P1.05-034 Neutrophil-To-Lymphocyte and Platelet-To-Lymphocyte Ratios as Prognostic Biomarkers in Early NSCLC Patients Treated with SABR

Stephen Mckay; Karen Moore; Jennifer Macphee; Jonathan Hicks; Graeme Lumsden; Vivienne Maclaren; Philip Mcloone; Stephen Harrow

首页> 外文期刊>Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer >P1.05-034 Neutrophil-To-Lymphocyte and Platelet-To-Lymphocyte Ratios as Prognostic Biomarkers in Early NSCLC Patients Treated with SABR

【24h】

P1.05-034 Neutrophil-To-Lymphocyte and Platelet-To-Lymphocyte Ratios as Prognostic Biomarkers in Early NSCLC Patients Treated with SABR

机译：P1.05-034中性粒细胞到淋巴细胞和血小板到淋巴细胞比例，作为早期NSCLC患者治疗SABR的预后生物标志物

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer》 |2017年第1期|共2页
作者
Stephen Mckay; Karen Moore; Jennifer Macphee; Jonathan Hicks; Graeme Lumsden; Vivienne Maclaren; Philip Mcloone; Stephen Harrow;
展开▼
作者单位

Beatson West of Scotland Cancer Centre;

Beatson West of Scotland Cancer Centre;

Beatson West of Scotland Cancer Centre;

Beatson West of Scotland Cancer Centre;

Beatson West of Scotland Cancer Centre;

Beatson West of Scotland Cancer Centre;

Institute of Health and Wellbeing University of Glasgow;

Beatson West of Scotland Cancer Centre;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. P1.05-034 Neutrophil-To-Lymphocyte and Platelet-To-Lymphocyte Ratios as Prognostic Biomarkers in Early NSCLC Patients Treated with SABR [J] . Stephen Mckay, Karen Moore, Jennifer Macphee, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第1期

机译：P1.05-034中性粒细胞到淋巴细胞和血小板到淋巴细胞比例，作为早期NSCLC患者治疗SABR的预后生物标志物
2. Pretreatment biomarkers as prognostic predictors of survival in patients with Pancreatic Cancer treated with Gemcitabine-based Therapy and 5-Fluorouracil: Neutrophil-to-lymphocyte ratio ivs/i Platelet-to-lymphocyte ratio [J] . Yungu Chen, Yuan Liao, Lek Man Lam, International Journal of Medical Sciences . 2020,第10期

机译：预处理生物标志物作为吉西他滨治疗和5氟尿嘧啶治疗的胰腺癌患者存活的预测预测因子：中性粒细胞至淋巴细胞比率血小板到淋巴细胞比例
3. Evaluation of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Prognostic Biomarkers for Elderly Patients with Glioblastoma Treated with Chemoradiation [J] . Ng S. S. Q., Chua G. W. Y., Kusumawidjaja G., International Journal of Radiation Oncology, Biology, Physics . 2017,第2Suppla期

机译：评价中性粒细胞对淋巴细胞比和血小板到淋巴细胞比例作为较凉胶质母细胞瘤的老年患者的预后生物标志物
4. Delta-Radiomics Signature For Prediction Of Survival In Advanced Nsclc Patients Treated With Immunotherapy [C] . B. Farina, A. D. Ramos Guerra, C. Palacios Miras, IEEE International Symposium on Biomedical Imaging . 2021

机译：用于预测免疫疗法治疗的高级NSCLC患者存活的三角洲 - 辐射瘤
5. Prognostic Biomarkers for Diffuse Large B Cell Lymphoma Patient Survival after Treatment with Chemotherapy: A Retrospective Analysis of 88 Cases [D] . Bushra, Hamama tul. 2019

机译：弥漫性大B细胞淋巴瘤化疗后患者生存的预后生物标志物：88例回顾性分析
6. Pretreatment biomarkers as prognostic predictors of survival in patients with Pancreatic Cancer treated with Gemcitabine-based Therapy and 5-Fluorouracil: Neutrophil-to-lymphocyte ratio vs Platelet-to-lymphocyte ratio [O] . Yungu Chen, Yuan Liao, Lek Man Lam, 2020

机译：以吉西他滨为基础的治疗和5-氟尿嘧啶治疗的胰腺癌患者的预处理预后生物标志物是生存率的预测指标：中性粒细胞与淋巴细胞之比vs血小板与淋巴细胞之比
7. Pretreatment biomarkers as prognostic predictors of survival in patients with Pancreatic Cancer treated with Gemcitabine-based Therapy and 5-Fluorouracil: Neutrophil-to-lymphocyte ratio vs Platelet-to-lymphocyte ratio [O] . Yungu Chen, Yuan Liao, Lek Man Lam, 2020

机译：预处理生物标志物作为牙科碱治疗胰腺癌和5氟尿嘧啶治疗的胰腺癌患者存活的预测预测因子：中性粒细胞对淋巴细胞比Vs血小板到淋巴细胞比率

P1.05-034 Neutrophil-To-Lymphocyte and Platelet-To-Lymphocyte Ratios as Prognostic Biomarkers in Early NSCLC Patients Treated with SABR

著录项

相似文献

相关主题

期刊订阅